Role of ganaton in antiemetic therapy. New treatment capacities

Cover Page

Cite item

Full Text

Abstract

The practical introduction of new effective drugs for the prevention and treatment of nausea and vomiting is one of the important constitu- ents of maintenance therapy in cancer patients, which helps maintain a good quality of life during drug treatment. This paper considers the main mechanisms of occurrence of nausea and vomiting and current recommendations for their prevention and gives the results of the authors’ studies evaluating the use of ganaton, a D2-receptor antagonist, alone and in combination with 5-HT3-receptor antagonists for the prevention and treatment of acute and delayed nausea and vomiting. The drug has shown a high efficacy and it is recommended for clinical application.

About the authors

A. V. Snegovoy

N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow

Author for correspondence.
Email: drsneg@gmail.com
Russian Federation

L. V. Manzyuk

N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow

Russian Federation

References

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2010



СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 36991 от  21.07.2009.